Drugs / AMG 133
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07429032 | Apr → Nov 2025 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT07428525 | Mar 2025 → Feb 2026 | — | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT07429045 | Mar → Nov 2025 | morbid obesity | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT07310563 | Dec 2024 → May 2025 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT06976372 | Aug → Dec 2024 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT05056246 | Sep 2021 → Apr 2022 | — | Amgen | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-12-01 | Amgen | AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022 amgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 133 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07429032 ↗ |
| Route | Subcutaneous | “Solution for SC injection” NCT05056246 ↗ |